Veracyte (NASDAQ:VCYT) Stock Price Target Lowered at Stephens

Veracyte (NASDAQ:VCYT) had its target price cut by Stephens from $55.00 to $40.00 in a research report released on Wednesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on the stock. Zacks Research downgraded shares of Veracyte from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Wall Street Zen lowered Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Piper Sandler decreased their price target on Veracyte from $54.00 to $30.00 and set an “overweight” rating on the stock in a research note on Tuesday. Needham & Company LLC decreased their price target on Veracyte from $69.00 to $46.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. Finally, Weiss Ratings lowered Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $44.50.

Veracyte Price Performance

Shares of VCYT stock opened at $25.11 on Wednesday. The firm has a market cap of $2.03 billion, a PE ratio of 15.83 and a beta of 1.98. The company has a 50-day moving average of $42.98 and a two-hundred day moving average of $42.59. Veracyte has a 1-year low of $21.91 and a 1-year high of $60.91.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.10. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. The business had revenue of $151.75 million during the quarter, compared to analysts’ expectations of $147.13 million. During the same period last year, the business earned $0.51 earnings per share. The business’s revenue for the quarter was up 15.1% on a year-over-year basis. Sell-side analysts anticipate that Veracyte will post 1.32 EPS for the current fiscal year.

Insider Activity at Veracyte

In other Veracyte news, Director Jens Holstein sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total transaction of $375,000.00. Following the sale, the director directly owned 27,471 shares in the company, valued at $1,373,550. This represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Muna Bhanji sold 1,864 shares of the stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $43.70, for a total transaction of $81,456.80. Following the sale, the director directly owned 40,854 shares in the company, valued at $1,785,319.80. This represents a 4.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 62,609 shares of company stock valued at $2,858,904. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Veracyte

Several large investors have recently added to or reduced their stakes in VCYT. BlackRock Inc. acquired a new stake in Veracyte during the 2nd quarter worth approximately $792,058,000. Congress Asset Management Co. acquired a new position in shares of Veracyte in the third quarter worth $89,971,000. William Blair Investment Management LLC acquired a new position in shares of Veracyte in the second quarter worth $84,078,000. Bank of America Corp DE acquired a new position in shares of Veracyte in the second quarter worth $64,737,000. Finally, GW&K Investment Management LLC grew its stake in shares of Veracyte by 70.1% in the third quarter. GW&K Investment Management LLC now owns 2,409,303 shares of the biotechnology company’s stock worth $110,924,000 after acquiring an additional 992,760 shares in the last quarter.

Key Veracyte News

Investors following VCYT have been watching these news items:

• Neutral Sentiment: Veracyte presented at the 2026 UBS Global Healthcare Conference, but the provided transcript listings do not identify new guidance or developments likely to change the outlook. Conference transcript
• Negative Sentiment: A securities-law firm announced an investigation related to Veracyte’s disclosure of Decipher Prostate growth risks. The notice points to below-expectation test volume and narrowed 2026 revenue guidance, which could keep investor attention on execution and legal risk. Investigation notice
• Negative Sentiment: UBS issued a pessimistic forecast for Veracyte, though the supplied report does not provide its specific estimates. Wall Street Zen also cut its rating to “Hold.” UBS forecast report

Veracyte Company Profile

Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.